Cytokines and the liver

Journal of Hepatology

Volumn 27, Issue 6, 1997, Pages 1120-1132

  Simpson, Kenneth J ^a   Lukacs, Nicholas W ^a   Colletti, Lisa ^b   Strieter, Robert M ^a   Kunkel, Steven L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHEMOKINE; CYTOKINE; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; CYTOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; LYMPHOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; THROMBOCYTE ACTIVATING FACTOR; THYMOSTIMULIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; HEPATITIS; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LIVER METABOLISM; LIVER METASTASIS; LIVER REGENERATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; VIRUS HEPATITIS;

EID: 0030776636     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80160-2     Document Type: Review

References (131)

1. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Rescott SM, Zimmerman GA. Platelet activating factor, a mediator for the clinician. J Intern Med. 238:1995;5-20.
2. Goetzl EJ, An SZ, Smith WL. Specificity of expression and effects of eicosanoid mediators in normal physiology and human disease. FASEB J. 9:1995;1051-1058.
3. Kozak SL, Platt EJ, Madani N, Ferro FE, Peden K, Kabat D. CD4, CXCR4 and CCR5 dependencies for infections by primary patient and laboratory adapted isolates of HIV type 1. J Virol. 71:1997;873-882.
4. Neurath AR, Strick N, Li YY. Cells transfected with human IL6 cDNA acquire binding sites for the hepatitis B virus envelope protein. J Exp Med. 176:1992;1561-1569.
5. Deaciuc IV, Alappat JM, McDonough KH, D'Souza NB. Effect of chronic alcohol consumption by rats on TNF alpha and IL6 clearance in vivo and by the isolated perfused liver. Biochem Pharmacol. 52:1996;891-899.
6. Thornton AJ, Ham J, Kunkel SL. Kupffer cell derived cytokines induced the synthesis of a leukocyte chemotactic peptide, interleukin 8, in human hepatoma and primary hepatocyte cultures. Hepatology. 15:1992;1112-1122.
7. Thornton AJ, Strieter RM, Lindley I, Baggiolini M, Kunkel SL. Cytokine induced gene expression of a neutrophil chemotactic factor/IL8 in human hepatocytes. J Immunol. 144:1990;2609-2613.
8. Lukacs NW, Streiter RM, Elner VM, Evanoff HL, Burdick MD, Kunkel SL. ICAM-1 mediates the expression of monocyte derived MIP1 alpha during monocyte endothelial cell interaction. Blood. 83:1994;1174-1178.
9. Lukacs NW, Streiter RM, Elner VM, Evanoff HL, Burdick MD, Kunkel SL. Production of chemokines, IL8 and MCP-1 during monocyte endothelial cell interactions. Blood. 86:1995;2767-2774.
10. Kurose I, Miura S, Higuchi H, Watanabe N, Kamegaya Y, Takaishi M, et al. Increased nitric-oxide synthase activity as a cause of mitochondrial dysfunction in rat hepatocytes, roles for tumor necrosis factor alpha. Hepatology. 24:1996;1185-1192.
11. Serizawa A, Nakamura S, Suzuki S, Baba S, Nakano M. Involvement of PAF in cytokine production and neutrophil activation after hepatic ischaemia-reperfusion. Hepatology. 23:1996;1656-1663.
12. Suzuki S, Toledopereyra LH. IL1 and TNF production as the initial stimulants of liver ischaemia and reperfusion injury. J Surg Res. 57:1994;253-258.
13. Shito M, Wakabayashi G, Ueda M, Shimazu M, Shirasugi N, Endo M, et al. IL1 receptor blockade reduces TNF production, tissue injury and mortality after hepatic ischaemia/reperfusion in the rat. Transplantation. 63:1997;143-148.
14. Colletti LM, Kunkel SL, Walz A, Burdick MD, Kunkel RG, Wilke CA, et al. The role of cytokine networks in the local liver injury following hepatic ischaemia/reperfusion in the rat. Hepatology. 23:1996;506-514.
15. Deutschman CS, Haber BA, Andrejko K, Cressman DE, Harrison R, Elenko E, et al. Increased expression of CINC in septic rat liver. Am J Physiol. 40:1996;R593-R600.
16. Colletti LM, Kunkel SL, Green M, Burdick MD, Streiter RM. Hepatic inflammation following 70% hepatectomy may be related to up-regulation of ENA-78. Shock. 6:1996;397-402.
17. Sato T, Asanuma Y, Masaki Y, Sato Y, Hatakeyama Y, Kusano T, Koyama K. Changes in TNF alpha and IL1 beta production following liver surgery on cirrhotic patients. Hepato-Gastroenterol. 43:1996;1148-1153.
18. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 10:1996;709-720.
19. Larapezzi E, Chirillo P, Morenootero R, Lopezcabrera M. Induction of TNF alpha production in human hepatocytes by the hepatitis B virus HBX protein. Hepatology. 24:1996;SS392.
20. Inagi R, Guntapong R, Nakao M, Ishino Y, Kawanishi K, Isegawa Y, et al. Human herpes virus-6 induces IL8 gene expression in human hepatoma cell line, Hep G2. J Med Virol. 49:1996;34-40.
21. Shiratori Y, Takada H, Hikiba Y, Nakata R, Okano K, Komatsu Y, et al. Production of chemotactic factor, interleukin 8 from hepatocytes exposed to ethanol. Hepatology. 18:1993;1477-1482.
22. Shiratori Y, Takada H, Hai K, Kiriyama H, Mawet E, Komatsu Y, et al. Effect of antiallergic agents on chemotaxis of neutrophils by stimulation of chemotactic factor released from hepatocytes exposed to ethanol. Dig Dis Sci. 39:1994;1569-1575.
23. Mawet E, Shiratori Y, Hikiba Y, Takada H, Yoshida H, Kano K, et al. CINC release from hepatocytes is modulated by Kupffer cells. Hepatology. 23:1996;353-358.
24. VanGool J, VanVugt H, Helle M, Aarden LA. The relation among stress, adrenaline, interleukins and acute phase proteins in the rat. Clin Immunol Immunopathol. 57:1990;200-210.
25. Knollé PA, Loser E, Protzer U, Duchmann R, Schmitt E, Rose John S, et al. Regulation of endotoxin induced IL6 production in the liver sinusoidal endothelial cells and Kupffer cells by IL10. Clin Exp Immunol. 107:1997;555-561.
26. Fernandezbotran R, Chilton PM, Ma YH. Soluble cytokine receptors. Adv Immunol. 63:1996;269-336.
27. Foxwell BMJ, Barrett K, Feldmann M. Cytokine receptors, structure and signal transduction. Clin Exp Immunol. 90:1992;161-169.
28. Van Den Abeele P, DeClercq W, Beyaert R, Fiers W. 2 TNF receptors, structure and function. Trends Cell Biol. 5:1995;392-399.
29. Horuk R. The IL8 receptor family. Immunology Today. 15:1994;169-174.
30. Schindeler C, Darnell JE. Transcriptional responses to polypeptide ligands, the JAK/STAT pathway. Ann Rev Biochem. 64:1995;621-651.
31. Mufson RA. The role of serine threonine phosphorylation in hemopoietic cytokine receptor signal transduction. FASEB J. 11:1997;37-44.
32. Darnay BG, Aggarwal BB. Early event sin TNF signaling. J Leukocyte Biol. 61:1997;559-566.
33. Diehl AM, Rai RM. Regulation of signal transduction during liver regeneration. FASEB J. 10:1996;215-227.
34. Harbrecht BG, Wang SC, Simmons RL, Billiar TR. cGMP and guanylate cyclase mediate LPS induced Kupffer cell TNF alpha synthesis. J Leukocyte Biol. 57:1995;297-302.
35. Chuang LM, Tai TY, Kahn RC, Wu HP, Lee SC, Lin BJ. Signal-transduction pathways for interleukin-4 and insulin in human hepatoma-cells. J Biochem. 120:1996;111-116.
36. Kordula T, Bugno M, Goldstein J, Travis J. Activation of signal transducer and activator of transcription 3 (STAT3) expression by interferon-gamma and interleukin-6 in hepatoma cells. Biochem Biophys Res Commun. 216:1995;999-1005.
37. Schaper F, Siewert E, GomezLechon MJ, Gatsios P, Sachs M, Birchmeier W, et al. Hepatocyte growth factor scatter factor (HGF/SF) signals via the STAT3/APRF transcription factor in human hepatoma cells and hepatocytes. FEBS Lett. 405:1997;99-103.
38. Campos SP, Wang YP, Baumann H. Insulin modulates STAT3 protein activation and gene transcription in hepatic cells. J Biol Chem. 271:1996;24418-24424.
39. Bird TA, Kyriakis JM, Tyshler L, Gayle M, Milne A, Virca GD. Interleukin-1 activates p54 mitogen activated protein (MAP) kinase kinase stress activated protein kinase by a pathway that is independent of p21(RAS), raf-1, and MAP kinase kinase. J Biol Chem. 269:1994;31836-31844.
40. Mendelson KG, Contois LR, Tevosian SG, Davis RJ, Paulson KE. Independent regulation of JNK/P38 MAP kinases by metabolic oxidative stress in the liver. Proc Natl Acad Sci USA. 93:1996;12908-12913.
41. Ahmad F, Goldstein BJ. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases. J Cell Biochem. 64:1997;117-127.
42. Liao W, Floren CH. Up-regulation of low-density-lipoprotein receptor activity by tumor necrosis factor, a process independent of tumor necrosis factor induced lipid synthesis and secretion. Lipids. 29:1994;679-684.
43. Skretting G, Gjernes E, Prydz H. Regulation of LCAT by TGF and IL6. Biochem Biophys Acta. 1255:1995;267-272.
44. Asumendi A, Alvarez A, Martinez I, Smedsrod B, Vidal-Vanaclocha F. Hepatic sinusoidal endothelium heterogeneity with respect to mannose receptor activity is IL1 dependent. Hepatology. 23:1996;1521-1529.
45. Moseley RH, Wang W, Takeda H, Lown K, Shick L, Ananthanarayanan M. Effect of endotoxin on bile acid transport in rat liver. Am J Physiol. 34:1996;G137-G146.
46. Green RM, Beier D, Gollan JL. Regulation of hepatic bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology. 111:1996;193-198.
47. Baumann H, Gauldie J. The acute phase response. Immunol Today. 15:1994;74-80.
48. Koj A. Initiation of the acute phase response and synthesis of cytokines. Biochem Biophys Acta. 1317:1996;84-94.
49. Moshage H. Cytokines and the hepatic acute phase response. J Pathol. 181:1997;257-266.
50. Banks RE, Forbes MA, Storr M, Higgenson J, Thompson D, Illingworth JM, et al. The acute phase response in patients receiving subcutaneous IL6. Clin Exp Immunol. 102:1995;217-223.
51. Harrison P, Downs T, Friese P, Wolf R, George JN, Burstein SA. Inhibition of the acute-phase response in-vivo by anti-gp130 monoclonal-antibodies. Br J Haematol. 95:1996;443-451.
52. McCoy R, Haviland DL, Molmenti EP, Ziambaras T, Wetsel RA, Perlmutter DH. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene-regulation. J Exp Med. 182:1995;207-217.
53. Buchner RR, Hugli TE, Ember JA, Morgan EL. Expression of functional receptors for human C5a anaphylatoxin (CD88) on the human hepatocellular-carcinoma cell line Hep G2; stimulation of acute phase protein specific mRNA and protein synthesis by human C5a anaphylatoxin. J Immunol. 155:1995;308-315.
54. Santucci L, Fiorucci S, Chiorean M, Brunori PM, Di Matteo FM, Sidoni A, et al. Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine sensitized mice. Gastroenterology. 111:1996;736-744.
55. Louis H, Moine OL, Peny M-O, Gulbis B, Nisol F, Goldman M, et al. Hepatoprotective role of interleukin 10 in galactosamine/lipopolysaccharide mouse liver injury. Gastroenterology. 132:1997;935-942.
56. Ganter F, Kusters S, Wendel A, Hatzelmann A, Schudt C, Teigs G. Protection from T cell mediated murine liver failure by phosphodiesterase inhibitors. J Pharmacol Exp Ther. 280:1997;53-60.
57. Leist M, Gantner F, Naumann, Bluethmann, Vogt K, Brigelius-Flohe R, et al. Tumor necrosis factor induced apoptosis during the poisoning of mice with hepatotoxins. Gastroenterology. 112:1997;923-934.
58. Knustle G, Leist M, Uhlig S, Revesz L, Feifel R, MacKenzie A, et al. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF alpha. Immunol Lett. 55:1997;5-10.
59. Bohlinger I, Leist M, Barsig J, Uhlig S, Teigs G, Wendel A. Interleukin I and nitric oxide protect against tumor necrosis factor α induced liver injury through distinct pathways. Hepatology. 22:1995;1829-1837.
60. Watanabe Y, Morita M, Akaike T. ConA induces perforin but not Fas mediated hepatic injury. Hepatology. 24:1996;702-710.
61. Leist M, Wendel A. A novel mechanism of murine hepatocyte death inducible by ConA. J Hepatol. 25:1996;948-959.
62. Mizuhara H, Uno M, Seki N, Yamashita M, Yamaoka M, Ogawa T, et al. Critical involvement of interferon gamma in the pathogenesis of T cell activation associated hepatitis and regulatory mechanisms of IL6 for the manifestations of hepatitis. Gastroenterology. 23:1996;1608-1615.
63. Bruck R, Shirin H, Hershkoviz R, Lider O, Kenet G, Aeed H, et al. Analysis of Arg-Gly-Asp mimetics and soluble receptor of TNF as theraputic modalities for ConA induced hepatitis in mice. Gut. 40:1997;133-138.
64. Okamoto T, Furuya M, Yamakawa T, Yamamura KI, Hino O. TNF alpha expression in the liver of the IFN transgenic mouse with chronic active hepatitis. Biochem Biophys Res Commun. 226:1996;762-768.
65. Chisari FV, Ferrari C. Hepatitis B immunopathogenesis. Ann Rev Immunol. 13:1995;29-60.
66. Guidotti LG, Borrow P, Hobbs MV, Matzke B, Gresser I, Oldstone MBA, et al. Viral cross talk, intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA. 93:1996;4589-4594.
67. Cavanaugh VJ, Guidotti LG, Chisari FV. IL12 inhibits hepatitis B viral replication in transgenic mice. J Virol. 71:1997;3236-3243.
68. Morita M, Watanabe Y, Akaike T. Protective effect of HGF on IFN gamma induced cytotoxicity in mouse hepatocytes. Hepatology. 21:1995;1585-1593.
69. Wu J, Zern MA. Modification of liposomes for liver targetting. J Hepatol. 24:1996;757-763.
70. Maher JJ, Scott MK, Saito JM, Burton MC. Adenovirus mediated expression of CINC in rat liver induces a neutrophilic hepatitis. Hepatology. 25:1997;624-630.
71. Means RT, Mendenhall CL, Worden BD, Moritz TE, Chedid A. EPO and cytokine levels in the anaemia of severed lcoholic liver disease. Alc Clin Exp Res. 20:1996;355-358.
72. Haeger M, Unander M, Andersson B, Tarkowski A, Arnestad JP. Increased release of TNF alpha and IL6 in women with the HELLP syndrome. Acta Obstet Gynecol Scand. 75:1996;695-701.
73. Keane HM, Sheron N, Goka J, Hughes RD, Williams R. Plasma inhibitory activity against TNF in fulminant hepatic failure. Clin Sci. 90:1996;77-80.
74. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection. Hepatology. 24:1996;6-9.
75. Spengler U, Zachoval R, Gallati H, Jung MC, Hoffman R, Reithmuller G, et al. Serum levels and in situ expression of TNF alpha and TNF alpha binding proteins in inflammatory liver diseases. Cytokine. 8:1996;864-872.
76. Malaguarnera M, DiFazio I, Romeo MA, Restuccia S, Laurino A, Trovato BA. Elevation of IL6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol. 32:1997;211-215.
77. Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, et al. Circulating and tissue levels of the neutrophil chemotaxin IL8 are elevated in severe acute alcoholic hepatitis. Hepatology. 18:1993;41-46.
78. Simonet S, Hughes TM, Nguyen HQ, Trebasky LD, Danilenko DM, Madlock ES. Long-term impaired neutrophil migration in mice overexpressing human IL8. J Clin Invest. 94:1994;1310-1319.
79. Lemoine O, Marchant A, DeGroote D, Azar C, Oldman M, DeViere J. Role of defective monocyte IL10 release in TNF alpha overproduction in alcoholic cirrhosis. Hepatology. 22:1995;1436-1439.
80. Mendoza EC, Paglieroni TG, Zeldis JB. Decreased PMA induced release of TNF alpha and IL1 beta from peripheral blood monocytes of patients infected with hepatitis C virus. J Infect Dis. 174:1996;842-844.
81. Kakumu S, Okumura A, Ishikawa T, Iwata K, Yano M, Yoshioka K. Production of IL10 and 12 by peripheral blood mononuclear cells in chronic hepatitis C virus infection. Clin Exp Immunol. 108:1997;138-143.
82. Llorente L, Richaudpatin Y, Alcocastillejos N, Ruizsoto R, Mercado MA, Orozco H, et al. Cytokine gene expression in cirrhotic and noncirrhotic human liver. J Hepatol. 24:1996;555-563.
83. Fang JWS, Shen WW, Meager A, Lau JYN. Activation of the TNF alpha system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol. 91:1996;748-753.
84. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1 associated cytokines. Hepatology. 24:1996;759-765.
85. Lohr HF, Schlaak JF, Kollmannsperger S, Dienes HP, Zum Büschenfelde KHM, Gerken G. Liver infiltrating and circulating CD4+ T cells in chronic hepatitis C. Liver. 16:1996;174-182.
86. Gorczynski RM, Adams RB, Levy GA, Chung SW. Correlation of peripheral blood lymphocyte and intragraft cytokine mRNA expression with rejection in orthotopic liver transplantation. Surgery. 120:1996;496-502.
87. Bertoletti A, D'Elios MM, Boni C, DeCarli M, Ziegnego AL, Durazzo M, et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and C virus infections. Gastroenterology. 112:1997;193-199.
88. Fukuda R, Ishimura N, Nguyen TX, Chowdhury A, Shihara S, Kohge N. The expression of IL2, IL4 and IFN mRNA using liver biopsies at different phases of acute exacerbation of hepatitis B. Clin Exp Immunol. 100:1995;446-451.
89. Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B virus core and e antigens elicit different Th cell subsets. J Virol. 71:1997;2192-2201.
90. Lohr HF, Schlaak JF, Gerken G, Fleischer B, Dienes HP, Zum Büschenfelde KHM. Phenotypical analysis and cytokine release of liver infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different aetiologies. Liver. 14:1994;161-166.
91. Harada K, Van de Water J, Leung PSC, Coppel RL, Ansari A, Nakanuma Y, et al. In situ nucleic acid hybridisation of cytokines in PBC: predominance of the Th1 subset. Hepatology. 25:1997;791-796.
92. Jones DEJ, Palmer JM, Leon MP, Yeaman SJ, Bassendine MF, Diamond AG. T cell responses to tuberculin PPD in PBC. Gut. 40:1997;277-283.
93. Maltby J, Wright S, Bird G, Sheron N. Chemokine levels in human liver homogenates. Hepatology. 24:1996;1156-1160.
94. Bautista AP. Chronic alcohol intoxication induces hepatic injury through enhanced macrophage inflammatory protein 2 production and ICAM-1 expression in the liver. Hepatology. 25:1997;335-342.
95. Martinez OM, Villanueva JC, Gershwin ME, Krams SM. Cytokine patterns and cytotoxic mediators in PBC. Hepatology. 21:1995;113-119.
96. Martinez OM, Ascher NL, Ferrell L, Villanueva JC, Lake J, Roberts JP, et al. Evidence for a nonclassical pathway of graft rejection involving IL5 and eosinophils. Transplantation. 55:1993;909-918.
97. Adams DH, Hubscher S, Fear J, Johnson J, Shaw S, Afford S. Hepatic exprssion of MIP1 alpha and MIP1 beta after liver transplantation. Transplantation. 61:1996;817-825.
98. Davis BH, Kresina TF. Hepatic fibrogenesis. Clin Lab Med. 16:1996;361-387.
99. Alcolando R, Arthur MJP, Iredale JP. Pathogenesis of hepatic fibrosis. Clin Sci. 92:1997;103-112.
100. Gressner AM, Lahme B, Brenzel A. Molecular dissection of the mitogenic effect of hepatocytes on cultured hepatic stellate cells. Hepatology. 22:1995;1507-1518.
101. Benyon RC, Pickering JA, Gaca MDA, Arthur MJP. Interactions between hepatic stellate cells and mast cells. J Hepatol. 26:1997;131. (Suppl. 1).
102. Farrell DJ, Hines JE, Walls AF, Kelly PJ, Bennett MK, Burt AD. Intrahepatic mast cells in chronic liver diseases. Hepatology. 22:1995;1175-1181.
103. Czaja MJ, Geerts A, Xu J, Schmiedeberg P, Ju Y. MCP-1 expression occurs in toxic liver injury and human disease. J Leukocyte Biol. 55:1994;120-126.
104. Xu Y, Rojkind M, Czaja MJ. Regulation of monocyte chemoattractant protein 1 by cytokines and oxygen free radicals in rat hepatic fat storing cells. Gastroenterology. 110:1996;1870-1877.
105. Hoffman AL, Rosen HR, Ljubimova JU, Sher L, Podesta LG, Demetriou AA, et al. Hepatic regeneration. Semin Liver Dis. 14:1994;190-210.
106. Fausto N, Webber EM. Liver regeneration. Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA. The Liver: Biology and Pathobiology. 1994;1059-1084 Raven Press Ltd, New York.
107. Diehl AM, Rai RM. Review, regulation of liver regeneration by proinflammataroy cytokines. J Gastroenterol Hepatol. 11:1996;466-470.
108. Bruccoleri A, Gallucci R, Germolec DR, Blackspear P, Simeonova P, Thurman RG, et al. Induction of early intermediate genes by tumour necrosis factor α contribute to liver repair following chemical induced hepatotoxicity. Hepatology. 25:1997;133-141.
109. Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by TNF: deficient liver regeneration in mice lacking type 1 TNF receptor. Proc Natl Acad Sci USA. 94:1997;1441-1446.
110. Rai RM, Loffreda S, Karp CL, Yang S-Q, Lin H-Z, Diehl AM. Kupffer cell depletion abolishes induction of interleukin 10 and permits the sustained overexpression of TNF alpha mRNA in the regenerating rat liver. Hepatology. 25:1997;889-895.
111. Cressman DE, Diamond RA, Taub R. Rapid activation of the Stat 3 transcription complex in liver regeneration. Hepatology. 21:1995;1443-1449.
112. Diehl AM, Yang SQ, Yin M, Lin HZ, Nelson S, Bagby G. Tumor necrosis factor alpha modulates CCAAT/enhancer binding proteins DNA binding activities and promotes hepatocyte specific gene expression during liver regeneration. Hepatology. 22:1995;252-261.
113. Taub R. Transcriptional control of liver regeneration. FASEB J. 10:1996;413-427.
114. Menegazzi M, DePrati A, Suzuki H, Shinozuka H, Pibiri M, Piga R, et al. Liver cell proliferation induced by nafenopin and cyproterone acetate is not associated with increases in activation of the transcription factors NK-kB and AP-1 or with expression of TNF alpha. Hepatology. 25:1997;585-592.
115. Gangopadhyay A, Bajenova O, Kelly TM, Thomas P. Carcinoembryonic antigen induces cytokine expression in Kupffer cells implications for hepatic metastasis for colorectal cancer. Cancer Res. 56:1996;4805-4810.
116. Sakamoto K, Masuda T, Mita S, Ishiko T, Nakashima Y, Arakawa H, et al. Interleukin-8 is constitutively and commonly produced by various human carcinoma cell-lines. Int J Clin Lab Res. 22:1992;216-219.
117. Matsuda Y, Kawata S, Nagase T, Maeda Y, Yamasaki E, Kiso S, et al. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma effects of serine protease inhibitor. Cancer. 73:1994;53-57.
118. Argiles JM, LopezSoriano FJ. Cancer cachexia: a key role for TNF? Int J Oncol. 10:1997;565-572.
119. Murray S, Schell K, McCarthy DO, Albertini MR. Tumor growth, weight loss and cytokines in SCID mice. Cancer Lett. 111:1997;111-115.
120. Costelli P, Llovera M, Carbo N, Garciamartinez C, Lopezsorianoq FJ, Argiles JM. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett. 95:1995;33-38.
121. Costelli P, Carbo N, Tessitore L, Bagby Gj, Lopezsoriano FJ, Argiles JM, et al. Tumor necrosis factor alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest. 92:1993;2783-2789.
122. Tilg H. New insights into the mechanisms of interferon alpha. Gastroenterology. 112:1997;1017-1021.
123. Adachi Y, Arii S, Funaki N, Higashitsuji H, Fujita S, Furutani M, et al. Tumoricidal activity of Kupffer cells augmented by anticancer drugs. Life Sci. 51:1992;177-183.
124. Karpoff HM, Tung C, Ng B, Fong YM. Interferon-gamma protects against hepatic tumor-growth in rats by increasing Kupffer cell tumoricidal activity. Hepatology. 24:1996;374-379.
125. Guo YJ, Che XY, Shen F, Xie TP, Ma J, Wang XN, et al. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med. 3:1997;451-455.
126. Huang H, Chen SH, Kosai K, Fenegold MJ, Woo SLC. Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther. 3:1996;980-987.
127. Balemans LTM, Mattijssen V, Steerenberg PA, Vandriel BEM, Demulder PHM, Denotter W. Locoregional therapy with polyethylene glycol modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea-pig induces T-cell mediated antitumor activity. Cancer Immunol Immunother. 37:1993;7-14.
128. Yeung AW, Pang YK, Tsang YC, Wong SW, Leung JS. Short duration in vitro interleukin-2 activated mononuclear cells for advanced cancer, a Hong-Kong biotherapy pilot study trial. Cancer. 71:1983;3633-3639.
129. Ferlazzo G, Scisca C, Lemmo R, Cavaliere R, Quartarone G, Adamo V, et al. Intralesional sonographically guided injections of lymphokine activated killer cells and recombinant IL2 for the treatment of liver tumours. J Immunother. 20:1997;158-163.
130. Yang R, Lin Q, Rescorla FJ, Grosfeld JL. Experimental liver cancer, improved response after hepatic artery ligation and infusion of tumor necrosis factor alpha and interferon-gamma. Surgery. 118:1995;768-774.
131. Balach G, Izzo F, Chiao P, Klostergaard J, Curley SA. Activation of human Kupffer cells by thymostimulin to produce cytotoxicity against human hepatocellular carcinoma. Ann Surg Oncol. 4:1997;149-155.